Grant awarded for new nasal spray vaccine

The Bill & Melinda Gates Foundation has awarded a $6 million grant to NanoBio Corp. for the creation of a new nasal spray vaccine.

The Ann Arbor, Mich.-based NanoBio, a spinoff company founded through the University of Michigan, will use the money to support the development of its no-needle nanoemulsion technology, according to

The company is hoping to create a nasally delivered vaccine for respiratory syncytial virus, a top cause of childhood hospitalizations. The virus is capable of causing bronchiolitis and pneumonia and, according to the Centers for Disease Control and Prevention, it can lead directly to asthma or pulmonary disease.

“It’s a respiratory infection, which we feel our technology is really well suited for," David Peralta, NanoBio’s chief financial officer, said, according to

This will be the second time the Bill & Melinda Gates Foundation has provided major funding for a nanemulsion technology project. In 2005, the University of Michigan received $6.3 million for research into nasal spray vaccines.

The foundation, which reports assets of $36.4 billion, distributed $3 billion in grants in 2009 alone. Of that $3 billion, at least $800 million was dedicated directly towards funding the development of new vaccines, reports.

NanoBio’s grant is one of the largest ever given by the Bill & Melinda Gates Foundation to a private, for-profit company. Peralta told that he believes the foundation chose NanoBio partly because of its nanoemulsion technology. Because it uses no needles and the vaccines can remain at room temperature, the technology would be helpful in aiding organizations working in the third world.